| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a01d7935508cbe002beb151d4efde669
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2005-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3073f7b19925d8596e076b04b11e1689
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bcdd832136992571e5d284135d2d1665
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6d2b0e41d07c1ed97c1706bf61c22ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7fb6a21f1593c3ff25ecbe47cb5aef57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ee312727d64af25884c0ff5e085acd9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_079ac1347c2113e8081e66abfe1cb962 |
| publicationDate |
2010-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EA-013752-B1 |
| titleOfInvention |
PREVENTION AND TREATMENT OF SYNUCLEOPATHIC AND AMYLOIDOGENIC DISEASES |
| abstract |
The present invention relates to improved agents and methods for treating diseases associated with synucleinopathic diseases, including the formation of Levi alpha synuclein bodies in the brains of patients. These methods are the introduction of agents that induce a favorable immune response against Levy bodies. These methods are especially useful for the prevention and treatment of Parkinson's disease. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012177997-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2765303-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9845327-B2 |
| priorityDate |
2004-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |